HuGE Literature Finder
Records
1
-
24
| Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC psychiatry 2021 Feb 21 (1): 70. Lu Jinjun, Yang Ye, Lu Jian, Wang Zuqing, He Yiping, Yan Yeliang, Fu Kai, Jiang Wenjuan, Xu Yunqing, Wu Renrong, Liu Wenqing, Zhao Jingpi |
| Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia. NPJ schizophrenia 2021 Jan 7 (1): 5. Shin Wonsuk, Bang Minji, Kim Anhye, Cho Doo-Yeoun, Lee Sang-Hy |
| Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy. Gene 2019 Apr . Swadi Asma A, Mohammad Bassim I, Hadi Najah R, Al-Aubaidy Hayder |
| ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting. Human psychopharmacology 2017 Dec . Papazisis Georgios, Goulas Antonios, Sarrigiannidis Alexios, Bargiota Stavroula, Antoniadis Diomidis, Raikos Nikolaos, Basgiouraki Emmanouela, Bozikas Vasileios P, Garyfallos Georgi |
| Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India. Asian journal of psychiatry 2017 Jul 29 174-182. Kaur Gurjit, Gupta Deepti, Chavan Bir Singh, Sinhmar Vikas, Prasad Rajendra, Tripathi Adarsh, Garg P D, Gupta Rajiv, Khurana Hitesh, Gautam Shiv, Margoob Mushtaq Ahmed, Aneja Jitend |
| A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information. PloS one 2017 12 (1): e0169214. Silva-Alves Mariana S, Secolin Rodrigo, Carvalho Benilton S, Yasuda Clarissa L, Bilevicius Elizabeth, Alvim Marina K M, Santos Renato O, Maurer-Morelli Claudia V, Cendes Fernando, Lopes-Cendes Isc |
| Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. Journal of clinical psychopharmacology 2015 Oct . Hwang Tzung-Jeng, Lo Wei-Ming, Chan Hung-Yu, Lin Ching-Feng, Hsieh Ming H, Liu Chen-Chun, Liu Chih-Min, Hwu Hai-Gwo, Kuo Ching-Hua, Chen Wei |
| CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Developmental medicine and child neurology 2014 Oct 56 (10): 990-4. Youngster Ilan, Zachor Ditza A, Gabis Lidia V, Bar-Chaim Adina, Benveniste-Levkovitz Patricia, Britzi Malka, Soback Stefan, Ziv-Baran Tomer, Berkovitch Matitia |
| CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenetics and genomics 2013 Nov 23 (11): 627-30. Almoguera Berta, Riveiro-Alvarez Rosa, Lopez-Castroman Jorge, Dorado Pedro, Vaquero-Lorenzo Concepción, Fernandez-Piqueras José, Llerena Adrián, Abad-Santos Francisco, Baca-García Enrique, Dal-Ré Rafael, Ayuso Carmen, |
| Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population. Oxidative medicine and cellular longevity 2013 2013 831969. Caccamo Daniela, Cesareo Eleonora, Mariani Serena, Raskovic Desanka, Ientile Riccardo, Currò Monica, Korkina Liudmila, De Luca Chia |
| Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. Paediatric drugs 2012 Dec 14 (6): 411-5. Khetani Justin D, Madadi Parvaz, Sommer Doron D, Reddy Desigen, Sistonen Johanna, Ross Colin J D, Carleton Bruce C, Hayden Michael R, Koren Gide |
| Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT. Journal of psychopharmacology (Oxford, England) 2012 Mar 26 (3): 408-18. Aitchison Katherine J, Tsapakis Evangelia M, Huezo-Diaz Patricia, Kerwin Robert W, Forsling Mary L, Wolff K |
| Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomarkers in medicine 2011 Aug 5 (4): 439-49. Ruaño Gualberto, Villagra David, Szarek Bonnie, Windemuth Andreas, Kocherla Mohan, Gorowski Krystyna, Berrezueta Christopher, Schwartz Harold I, Goethe Jo |
| Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes. Toxicology and applied pharmacology 2010 Nov 248 (3): 285-92. De Luca Chiara, Scordo Maria G, Cesareo Eleonora, Pastore Saveria, Mariani Serena, Maiani Gianluca, Stancato Andrea, Loreti Beatrice, Valacchi Giuseppe, Lubrano Carla, Raskovic Desanka, De Padova Luigia, Genovesi Giuseppe, Korkina Liudmila |
| Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology 2010 Feb 30 (1): 11-7. Murata Yusuke, Kobayashi Daisuke, Imuta Nanae, Haraguchi Koichi, Ieiri Ichiro, Nishimura Ryoji, Koyama Susumu, Mine Kazuno |
| Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. European journal of clinical pharmacology 2009 Apr 65 (4): 355-63. Veiga M I, Asimus S, Ferreira P E, Martins J P, Cavaco I, Ribeiro V, Hai T N, Petzold M G, Björkman A, Ashton M, Gil J |
| CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009 59 (4): 222-6. Kobylecki Camilla J, Jakobsen Klaus D, Hansen Thomas, Jakobsen Ida V, Rasmussen Henrik B, Werge Thom |
| Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndrome. Pharmacogenomics 2008 Aug 9 (8): 1163-5. Goldenberg Naila, Glueck Charles |
| Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. European journal of clinical pharmacology 2007 Nov 63 (11): 991-6. Kato Daiji, Kawanishi Chiaki, Kishida Ikuko, Furuno Taku, Suzuki Kyoko, Onishi Hideki, Hirayasu Yosh |
| Risperidone-related weight gain: genetic and nongenetic predictors. Journal of clinical psychopharmacology 2006 Apr 26 (2): 128-34. Lane Hsien-Yuan, Liu Yi-Ching, Huang Chieh-Liang, Chang Yue-Cune, Wu Po-Lun, Lu Chung-Ta, Chang Wen- |
| Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. International clinical psychopharmacology 2005 Mar 20 (2): 71-8. Kakihara Shingo, Yoshimura Reiji, Shinkai Koji, Matsumoto Chima, Goto Makiko, Kaji Kyoko, Yamada Yasuhisa, Ueda Nobuhisa, Ohmori Osamu, Nakamura J |
| Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. International journal of epidemiology 2004 Oct 33 (5): 971-8. McKeown-Eyssen Gail, Baines Cornelia, Cole David E C, Riley Nicole, Tyndale Rachel F, Marshall Lynn, Jazmaji Vartou |
| Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatric genetics 2000 Sep 10 (3): 145-7. Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka |
| A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia. Indian journal of psychological medicine 0 40 (4): 335-342. Chavan Bir S, Kaur Gurjit, Gupta Deepti, Aneja Jitend |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 12, 2022
- Content source: